WO2005082001A3 - Advanced isothiazole based protein kinase inhibitors - Google Patents

Advanced isothiazole based protein kinase inhibitors Download PDF

Info

Publication number
WO2005082001A3
WO2005082001A3 PCT/US2005/005875 US2005005875W WO2005082001A3 WO 2005082001 A3 WO2005082001 A3 WO 2005082001A3 US 2005005875 W US2005005875 W US 2005005875W WO 2005082001 A3 WO2005082001 A3 WO 2005082001A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
advanced
kinase inhibitors
based protein
isothiazole
Prior art date
Application number
PCT/US2005/005875
Other languages
French (fr)
Other versions
WO2005082001A2 (en
Inventor
Congxin Liang
Original Assignee
Scripps Research Inst
Congxin Liang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Congxin Liang filed Critical Scripps Research Inst
Publication of WO2005082001A2 publication Critical patent/WO2005082001A2/en
Publication of WO2005082001A3 publication Critical patent/WO2005082001A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Hydroxy containing isothiazole base derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
PCT/US2005/005875 2004-02-20 2005-02-22 Advanced isothiazole based protein kinase inhibitors WO2005082001A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54653804P 2004-02-20 2004-02-20
US60/546,538 2004-02-20

Publications (2)

Publication Number Publication Date
WO2005082001A2 WO2005082001A2 (en) 2005-09-09
WO2005082001A3 true WO2005082001A3 (en) 2006-03-02

Family

ID=34910785

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/005859 WO2005081997A2 (en) 2004-02-20 2005-02-22 Isothiazole based protein kinase inhibitors
PCT/US2005/005875 WO2005082001A2 (en) 2004-02-20 2005-02-22 Advanced isothiazole based protein kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005859 WO2005081997A2 (en) 2004-02-20 2005-02-22 Isothiazole based protein kinase inhibitors

Country Status (1)

Country Link
WO (2) WO2005081997A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184525B1 (en) * 2011-12-28 2020-10-28 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboxamide derivatives as kinase inhibitors
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548526B2 (en) * 1998-06-04 2003-04-15 Pfizer Inc Isothiazole derivatives useful as anticancer agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548526B2 (en) * 1998-06-04 2003-04-15 Pfizer Inc Isothiazole derivatives useful as anticancer agents

Also Published As

Publication number Publication date
WO2005081997A2 (en) 2005-09-09
WO2005081997A3 (en) 2006-05-11
WO2005082001A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2005097137A3 (en) Advanced quinazoline based protein kinase inhibitors
WO2008033746A3 (en) Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
TW200734327A (en) Aminopyrimidines useful as kinase inhibitors
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
WO2008082839A3 (en) Pim kinase inhibitors as cancer chemotherapeutics
WO2006031806A3 (en) 2-thiopyrimidinones as therapeutic agents
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
MX2009004771A (en) Tricyclic heteroaryl compounds useful as inhibitors of janus kinase.
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
WO2008033745A3 (en) Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
WO2007081901A3 (en) Pyrimidinone derivatives as protein kinase inhibitors
WO2005082001A3 (en) Advanced isothiazole based protein kinase inhibitors
WO2005053614A3 (en) Advanced indolinone based protein kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase